Defining the optimal dose for remote ischaemic preconditioning in adult patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass: a randomised controlled trial

A Randomised Controlled Trial in Adult Patients Undergoing Coronary Artery Bypass Graft Surgery Designed to Determine the Optimal Dose for Remote Ischaemic Preconditioning Compared to No Remote Ischaemic Preconditioning and Measuring the Primary Outcome of Area Under the Curve for Troponin to 72 hours Post Aortic Cross Clamp Removal.

Status

Terminated

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000876099

Enrollment

Registered

2010-10-19

Start date

2010-12-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Remote ischaemic preconditioning is a technique that has been shown to reduce damage to the heart muscle while undergoing coronary artery bypass graft surgery. This study is designed to determine what dose of remote ischaemic preconditioning is best.

Interventions

Inflation of a pneumatic tourniquet device on an upper limb for one, two or three periods of five minute at a time to induce remote ischaemic preconditioning (assignment to control, one, two or three cuff inflations will be by randomisation using a computer generated list of random numbers). Each period of inflation involves inflation to a pressure of 200mmHg for five minutes and is followed by five minutes of deflation.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

Undergoing coronary artery bypass graft surgery with cardiopulmonary bypass

Exclusion criteria

1. documented ejection fraction <50%, 2. concurrent valvular surgery, 3. myocardial infarction within 21 days, 4. possible radial artery harvesting, 5. planned cross-clamp fibrillation, 6. >85 years of age, 7. peripheral vascular disease affecting the upper limbs 8. taking the sulphonylurea glibenclamide

Outcome results